APO Research
Talk to an analyst

APO RESEARCH · REPORT

PDE5 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global PDE5 Inhibitors Industry Growth and Trends Forecast to 2032

28 December 2025120 pages

Choose your research edition.

Industry ResearchPDE5 Inhibitors Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal PDE5 Inhibitors Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal PDE5 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PDE5 Inhibitors Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal PDE5 Inhibitors Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global PDE5 Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for PDE5 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for PDE5 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PDE5 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PDE5 Inhibitors include Alkem, Amneal Pharmaceuticals, Aurobindo Pharma, Chartwell, Cipla, Cristália, Dong-A Pharmaceutical, Dr. Reddy's Laboratories and Eugia Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global PDE5 Inhibitors market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The PDE5 Inhibitors market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global PDE5 Inhibitors market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to PDE5 Inhibitors.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global PDE5 Inhibitors market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

PDE5 Inhibitors Market by Company

Alkem

Amneal Pharmaceuticals

Aurobindo Pharma

Chartwell

Cipla

Cristália

Dong-A Pharmaceutical

Dr. Reddy's Laboratories

Eugia Pharma

Hetero

Lupin

Metuchen Pharmaceuticals

MSN

SK Chemicals Life Science

Sun Pharma

Teva

Watson Laboratories

Zydus

Guangzhou Baiyunshan Pharmaceutical

Haisco Pharmaceutical

Pfizer

Regenex Pharmaceutical

Eli Lilly

Qilu Pharmaceutical

Shanghai Huilun Pharmaceutical

Sichuan Kelun Pharmaceutical

Yangtze River Pharmaceutical

PDE5 Inhibitors Segment by Type

Avanafil

Vardenafil

Lodenafil

Mirodenafil

Tadalafil

Udenafil

Sildenafil

Other

PDE5 Inhibitors Segment by Application

Reilly's Phenomena

Pulmonary Hypertension

Erectile Dysfunction (ED)

Other

PDE5 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PDE5 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PDE5 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PDE5 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PDE5 Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of PDE5 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Avanafil Table 2. Major Company of Vardenafil Table 3. Major Company of Lodenafil Table 4. Major Company of Mirodenafil Table 5. Major Company of Tadalafil Table 6. Major Company of Udenafil Table 7. Major Company of Sildenafil Table 8. Major Company of Other Table 9. Global PDE5 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 10. Global PDE5 Inhibitors Sales by Type (2021-2026) & (K Units) Table 11. Global PDE5 Inhibitors Sales Market Share in Volume by Type (2021-2026) Table 12. Global PDE5 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 13. Global PDE5 Inhibitors Sales Market Share in Value by Type (2021-2026) Table 14. Global PDE5 Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 15. Global PDE5 Inhibitors Sales by Type (2027-2032) & (K Units) Table 16. Global PDE5 Inhibitors Sales Market Share in Volume by Type (2027-2032) Table 17. Global PDE5 Inhibitors Sales by Type (2027-2032) & (US$ Million) Table 18. Global PDE5 Inhibitors Sales Market Share in Value by Type (2027-2032) Table 19. Global PDE5 Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 20. North America PDE5 Inhibitors Sales by Type (2021-2026) & (K Units) Table 21. North America PDE5 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 22. Europe PDE5 Inhibitors Sales by Type (2021-2026) & (K Units) Table 23. Europe PDE5 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 24. Asia-Pacific PDE5 Inhibitors Sales by Type (2021-2026) & (K Units) Table 25. Asia-Pacific PDE5 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 26. Latin America PDE5 Inhibitors Sales by Type (2021-2026) & (K Units) Table 27. Latin America PDE5 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 28. Middle East and Africa PDE5 Inhibitors Sales by Type (2021-2026) & (K Units) Table 29. Middle East and Africa PDE5 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 30. PDE5 Inhibitors Industry Trends Table 31. PDE5 Inhibitors Industry Drivers Table 32. PDE5 Inhibitors Industry Opportunities and Challenges Table 33. PDE5 Inhibitors Industry Restraints Table 34. Global PDE5 Inhibitors Sales Revenue by Company (US$ Million) & (2021-2026) Table 35. Global PDE5 Inhibitors Revenue Market Share by Company (2021-2026) Table 36. Global PDE5 Inhibitors Sales by Company (2021-2026) & (K Units) Table 37. Global PDE5 Inhibitors Sales Share by Company (2021-2026) Table 38. Global PDE5 Inhibitors Market Price by Company (2021-2026) & (US$/Unit) Table 39. Global PDE5 Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026 Table 40. Global PDE5 Inhibitors Major Company Production Sites and Headquarters Table 41. Global PDE5 Inhibitors Company, Product Type & Application Table 42. Global PDE5 Inhibitors Company Establishment Date Table 43. Global Company Market Concentration Ratio (CR5 and HHI) Table 44. Global PDE5 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 45. Global PDE5 Inhibitors Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 46. Global PDE5 Inhibitors Sales by Region (2021-2026) & (K Units) Table 47. Global PDE5 Inhibitors Sales Market Share in Volume by Region (2021-2026) Table 48. Global PDE5 Inhibitors Sales by Region (2021-2026) & (US$ Million) Table 49. Global PDE5 Inhibitors Sales Market Share in Value by Region (2021-2026) Table 50. Global PDE5 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Global PDE5 Inhibitors Sales by Region (2027-2032) & (K Units) Table 52. Global PDE5 Inhibitors Sales Market Share in Volume by Region (2027-2032) Table 53. Global PDE5 Inhibitors Sales by Region (2027-2032) & (US$ Million) Table 54. Global PDE5 Inhibitors Sales Market Share in Value by Region (2027-2032) Table 55. Global PDE5 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 56. Global PDE5 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 57. Global PDE5 Inhibitors Sales by Application (2021-2026) & (K Units) Table 58. Global PDE5 Inhibitors Sales Market Share in Volume by Application (2021-2026) Table 59. Global PDE5 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 60. Global PDE5 Inhibitors Sales Market Share in Value by Application (2021-2026) Table 61. Global PDE5 Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 62. Global PDE5 Inhibitors Sales by Application (2027-2032) & (K Units) Table 63. Global PDE5 Inhibitors Sales Market Share in Volume by Application (2027-2032) Table 64. Global PDE5 Inhibitors Sales by Application (2027-2032) & (US$ Million) Table 65. Global PDE5 Inhibitors Sales Market Share in Value by Application (2027-2032) Table 66. Global PDE5 Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 67. North America PDE5 Inhibitors Sales by Application (2021-2026) & (K Units) Table 68. North America PDE5 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 69. Europe PDE5 Inhibitors Sales by Application (2021-2026) & (K Units) Table 70. Europe PDE5 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 71. Asia-Pacific PDE5 Inhibitors Sales by Application (2021-2026) & (K Units) Table 72. Asia-Pacific PDE5 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 73. Latin America PDE5 Inhibitors Sales by Application (2021-2026) & (K Units) Table 74. Latin America PDE5 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 75. Middle East and Africa PDE5 Inhibitors Sales by Application (2021-2026) & (K Units) Table 76. Middle East and Africa PDE5 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 77. Alkem Company Information Table 78. Alkem Business Overview Table 79. Alkem PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Alkem PDE5 Inhibitors Product Portfolio Table 81. Alkem Recent Development Table 82. Amneal Pharmaceuticals Company Information Table 83. Amneal Pharmaceuticals Business Overview Table 84. Amneal Pharmaceuticals PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Amneal Pharmaceuticals PDE5 Inhibitors Product Portfolio Table 86. Amneal Pharmaceuticals Recent Development Table 87. Aurobindo Pharma Company Information Table 88. Aurobindo Pharma Business Overview Table 89. Aurobindo Pharma PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Aurobindo Pharma PDE5 Inhibitors Product Portfolio Table 91. Aurobindo Pharma Recent Development Table 92. Chartwell Company Information Table 93. Chartwell Business Overview Table 94. Chartwell PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Chartwell PDE5 Inhibitors Product Portfolio Table 96. Chartwell Recent Development Table 97. Cipla Company Information Table 98. Cipla Business Overview Table 99. Cipla PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Cipla PDE5 Inhibitors Product Portfolio Table 101. Cipla Recent Development Table 102. Cristália Company Information Table 103. Cristália Business Overview Table 104. Cristália PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Cristália PDE5 Inhibitors Product Portfolio Table 106. Cristália Recent Development Table 107. Dong-A Pharmaceutical Company Information Table 108. Dong-A Pharmaceutical Business Overview Table 109. Dong-A Pharmaceutical PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Dong-A Pharmaceutical PDE5 Inhibitors Product Portfolio Table 111. Dong-A Pharmaceutical Recent Development Table 112. Dr. Reddy's Laboratories Company Information Table 113. Dr. Reddy's Laboratories Business Overview Table 114. Dr. Reddy's Laboratories PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Dr. Reddy's Laboratories PDE5 Inhibitors Product Portfolio Table 116. Dr. Reddy's Laboratories Recent Development Table 117. Eugia Pharma Company Information Table 118. Eugia Pharma Business Overview Table 119. Eugia Pharma PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Eugia Pharma PDE5 Inhibitors Product Portfolio Table 121. Eugia Pharma Recent Development Table 122. Hetero Company Information Table 123. Hetero Business Overview Table 124. Hetero PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Hetero PDE5 Inhibitors Product Portfolio Table 126. Hetero Recent Development Table 127. Lupin Company Information Table 128. Lupin Business Overview Table 129. Lupin PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Lupin PDE5 Inhibitors Product Portfolio Table 131. Lupin Recent Development Table 132. Metuchen Pharmaceuticals Company Information Table 133. Metuchen Pharmaceuticals Business Overview Table 134. Metuchen Pharmaceuticals PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Metuchen Pharmaceuticals PDE5 Inhibitors Product Portfolio Table 136. Metuchen Pharmaceuticals Recent Development Table 137. MSN Company Information Table 138. MSN Business Overview Table 139. MSN PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. MSN PDE5 Inhibitors Product Portfolio Table 141. MSN Recent Development Table 142. SK Chemicals Life Science Company Information Table 143. SK Chemicals Life Science Business Overview Table 144. SK Chemicals Life Science PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. SK Chemicals Life Science PDE5 Inhibitors Product Portfolio Table 146. SK Chemicals Life Science Recent Development Table 147. Sun Pharma Company Information Table 148. Sun Pharma Business Overview Table 149. Sun Pharma PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Sun Pharma PDE5 Inhibitors Product Portfolio Table 151. Sun Pharma Recent Development Table 152. Teva Company Information Table 153. Teva Business Overview Table 154. Teva PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Teva PDE5 Inhibitors Product Portfolio Table 156. Teva Recent Development Table 157. Watson Laboratories Company Information Table 158. Watson Laboratories Business Overview Table 159. Watson Laboratories PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Watson Laboratories PDE5 Inhibitors Product Portfolio Table 161. Watson Laboratories Recent Development Table 162. Zydus Company Information Table 163. Zydus Business Overview Table 164. Zydus PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Zydus PDE5 Inhibitors Product Portfolio Table 166. Zydus Recent Development Table 167. Guangzhou Baiyunshan Pharmaceutical Company Information Table 168. Guangzhou Baiyunshan Pharmaceutical Business Overview Table 169. Guangzhou Baiyunshan Pharmaceutical PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Guangzhou Baiyunshan Pharmaceutical PDE5 Inhibitors Product Portfolio Table 171. Guangzhou Baiyunshan Pharmaceutical Recent Development Table 172. Haisco Pharmaceutical Company Information Table 173. Haisco Pharmaceutical Business Overview Table 174. Haisco Pharmaceutical PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. Haisco Pharmaceutical PDE5 Inhibitors Product Portfolio Table 176. Haisco Pharmaceutical Recent Development Table 177. Pfizer Company Information Table 178. Pfizer Business Overview Table 179. Pfizer PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 180. Pfizer PDE5 Inhibitors Product Portfolio Table 181. Pfizer Recent Development Table 182. Regenex Pharmaceutical Company Information Table 183. Regenex Pharmaceutical Business Overview Table 184. Regenex Pharmaceutical PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 185. Regenex Pharmaceutical PDE5 Inhibitors Product Portfolio Table 186. Regenex Pharmaceutical Recent Development Table 187. Eli Lilly Company Information Table 188. Eli Lilly Business Overview Table 189. Eli Lilly PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 190. Eli Lilly PDE5 Inhibitors Product Portfolio Table 191. Eli Lilly Recent Development Table 192. Qilu Pharmaceutical Company Information Table 193. Qilu Pharmaceutical Business Overview Table 194. Qilu Pharmaceutical PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 195. Qilu Pharmaceutical PDE5 Inhibitors Product Portfolio Table 196. Qilu Pharmaceutical Recent Development Table 197. Shanghai Huilun Pharmaceutical Company Information Table 198. Shanghai Huilun Pharmaceutical Business Overview Table 199. Shanghai Huilun Pharmaceutical PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 200. Shanghai Huilun Pharmaceutical PDE5 Inhibitors Product Portfolio Table 201. Shanghai Huilun Pharmaceutical Recent Development Table 202. Sichuan Kelun Pharmaceutical Company Information Table 203. Sichuan Kelun Pharmaceutical Business Overview Table 204. Sichuan Kelun Pharmaceutical PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 205. Sichuan Kelun Pharmaceutical PDE5 Inhibitors Product Portfolio Table 206. Sichuan Kelun Pharmaceutical Recent Development Table 207. Yangtze River Pharmaceutical Company Information Table 208. Yangtze River Pharmaceutical Business Overview Table 209. Yangtze River Pharmaceutical PDE5 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 210. Yangtze River Pharmaceutical PDE5 Inhibitors Product Portfolio Table 211. Yangtze River Pharmaceutical Recent Development Table 212. North America PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 213. North America PDE5 Inhibitors Sales by Country (2021-2026) & (K Units) Table 214. North America PDE5 Inhibitors Sales Market Share by Country (2021-2026) Table 215. North America PDE5 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 216. North America PDE5 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 217. North America PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 218. North America PDE5 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 219. North America PDE5 Inhibitors Market Share by Country (2021-2026) Table 220. North America PDE5 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 221. North America PDE5 Inhibitors Market Share Forecast by Country (2027-2032) Table 222. Europe PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 223. Europe PDE5 Inhibitors Sales by Country (2021-2026) & (K Units) Table 224. Europe PDE5 Inhibitors Sales Market Share by Country (2021-2026) Table 225. Europe PDE5 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 226. Europe PDE5 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 227. Europe PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 228. Europe PDE5 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 229. Europe PDE5 Inhibitors Market Share by Country (2021-2026) Table 230. Europe PDE5 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 231. Europe PDE5 Inhibitors Market Share Forecast by Country (2027-2032) Table 232. Asia-Pacific PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 233. Asia-Pacific PDE5 Inhibitors Sales by Country (2021-2026) & (K Units) Table 234. Asia-Pacific PDE5 Inhibitors Sales Market Share by Country (2021-2026) Table 235. Asia-Pacific PDE5 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 236. Asia-Pacific PDE5 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 237. Asia-Pacific PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 238. Asia-Pacific PDE5 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 239. Asia-Pacific PDE5 Inhibitors Market Share by Country (2021-2026) Table 240. Asia-Pacific PDE5 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 241. Asia-Pacific PDE5 Inhibitors Market Share Forecast by Country (2027-2032) Table 242. Latin America PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 243. Latin America PDE5 Inhibitors Sales by Country (2021-2026) & (K Units) Table 244. Latin America PDE5 Inhibitors Sales Market Share by Country (2021-2026) Table 245. Latin America PDE5 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 246. Latin America PDE5 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 247. Latin America PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 248. Latin America PDE5 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 249. Latin America PDE5 Inhibitors Market Share by Country (2021-2026) Table 250. Latin America PDE5 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 251. Latin America PDE5 Inhibitors Market Share Forecast by Country (2027-2032) Table 252. Middle East and Africa PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 253. Middle East and Africa PDE5 Inhibitors Sales by Country (2021-2026) & (K Units) Table 254. Middle East and Africa PDE5 Inhibitors Sales Market Share by Country (2021-2026) Table 255. Middle East and Africa PDE5 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 256. Middle East and Africa PDE5 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 257. Middle East and Africa PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 258. Middle East and Africa PDE5 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 259. Middle East and Africa PDE5 Inhibitors Market Share by Country (2021-2026) Table 260. Middle East and Africa PDE5 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 261. Middle East and Africa PDE5 Inhibitors Market Share Forecast by Country (2027-2032) Table 262. Key Raw Materials Table 263. Raw Materials Key Suppliers Table 264. PDE5 Inhibitors Distributors List Table 265. PDE5 Inhibitors Customers List Table 266. Research Programs/Design for This Report Table 267. Authors List of This Report Table 268. Secondary Sources Table 269. Primary Sources List of Figures Figure 1. PDE5 Inhibitors Image Figure 2. Global PDE5 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PDE5 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global PDE5 Inhibitors Sales (2021-2032) & (K Units) Figure 5. Avanafil Image Figure 6. Global Avanafil Sales YoY Growth (2021-2032) & (K Units) Figure 7. Vardenafil Image Figure 8. Global Vardenafil Sales YoY Growth (2021-2032) & (K Units) Figure 9. Lodenafil Image Figure 10. Global Lodenafil Sales YoY Growth (2021-2032) & (K Units) Figure 11. Mirodenafil Image Figure 12. Global Mirodenafil Sales YoY Growth (2021-2032) & (K Units) Figure 13. Tadalafil Image Figure 14. Global Tadalafil Sales YoY Growth (2021-2032) & (K Units) Figure 15. Udenafil Image Figure 16. Global Udenafil Sales YoY Growth (2021-2032) & (K Units) Figure 17. Sildenafil Image Figure 18. Global Sildenafil Sales YoY Growth (2021-2032) & (K Units) Figure 19. Other Image Figure 20. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 21. Global PDE5 Inhibitors Market Size Overview by Type (2021-2032) & (US$ Million) Figure 22. Global PDE5 Inhibitors Market Share by Type 2025 VS 2032 Figure 23. North America PDE5 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 24. North America PDE5 Inhibitors Sales Market Share in Value by Type in 2025 Figure 25. Europe PDE5 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 26. Europe PDE5 Inhibitors Sales Market Share in Value by Type in 2025 Figure 27. Asia-Pacific PDE5 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 28. Asia-Pacific PDE5 Inhibitors Sales Market Share in Value by Type in 2025 Figure 29. Latin America PDE5 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 30. Latin America PDE5 Inhibitors Sales Market Share in Value by Type in 2025 Figure 31. Middle East and Africa PDE5 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 32. Middle East and Africa PDE5 Inhibitors Sales Market Share in Value by Type in 2025 Figure 33. Global Top 5 and 10 PDE5 Inhibitors Players Market Share by Revenue in 2025 Figure 34. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 35. Reilly's Phenomena Image Figure 36. Global Reilly's Phenomena Sales YoY Growth (2021-2032) & (K Units) Figure 37. Pulmonary Hypertension Image Figure 38. Global Pulmonary Hypertension Sales YoY Growth (2021-2032) & (K Units) Figure 39. Erectile Dysfunction (ED) Image Figure 40. Global Erectile Dysfunction (ED) Sales YoY Growth (2021-2032) & (K Units) Figure 41. Other Image Figure 42. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 43. Global PDE5 Inhibitors Market Size Overview by Application (2021-2032) & (US$ Million) Figure 44. Global PDE5 Inhibitors Market Share by Application 2025 VS 2032 Figure 45. North America PDE5 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 46. North America PDE5 Inhibitors Sales Market Share in Value by Application in 2025 Figure 47. Europe PDE5 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 48. Europe PDE5 Inhibitors Sales Market Share in Value by Application in 2025 Figure 49. Asia-Pacific PDE5 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 50. Asia-Pacific PDE5 Inhibitors Sales Market Share in Value by Application in 2025 Figure 51. Latin America PDE5 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 52. Latin America PDE5 Inhibitors Sales Market Share in Value by Application in 2025 Figure 53. Middle East and Africa PDE5 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 54. Middle East and Africa PDE5 Inhibitors Sales Market Share in Value by Application in 2025 Figure 55. North America PDE5 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. North America PDE5 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. North America PDE5 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. North America PDE5 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe PDE5 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Europe PDE5 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe PDE5 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Europe PDE5 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific PDE5 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Asia-Pacific PDE5 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific PDE5 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Asia-Pacific PDE5 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America PDE5 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Latin America PDE5 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Latin America PDE5 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Latin America PDE5 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa PDE5 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 72. Middle East and Africa PDE5 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 73. Middle East and Africa PDE5 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 74. Middle East and Africa PDE5 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 75. PDE5 Inhibitors Value Chain Figure 76. Key Raw Materials Price Figure 77. Manufacturing Cost Structure Figure 78. PDE5 Inhibitors Production Mode & Process Figure 79. Direct Comparison with Distribution Share Figure 80. Distributors Profiles Figure 81. Years Considered Figure 82. Research Process Figure 83. Key Executives Interviewed

Scope & coverage.

Types
  • Avanafil
  • Vardenafil
  • Lodenafil
  • Mirodenafil
  • Tadalafil
  • Udenafil
  • Sildenafil
  • Other
Applications
  • Reilly's Phenomena
  • Pulmonary Hypertension
  • Erectile Dysfunction (ED)
  • Other
Companies covered
  • Alkem
  • Amneal Pharmaceuticals
  • Aurobindo Pharma
  • Chartwell
  • Cipla
  • Cristália
  • Dong-A Pharmaceutical
  • Dr. Reddy's Laboratories
  • Eugia Pharma
  • Hetero
  • Lupin
  • Metuchen Pharmaceuticals
  • MSN
  • SK Chemicals Life Science
  • Sun Pharma
  • Teva
  • Watson Laboratories
  • Zydus
  • Guangzhou Baiyunshan Pharmaceutical
  • Haisco Pharmaceutical
  • Pfizer
  • Regenex Pharmaceutical
  • Eli Lilly
  • Qilu Pharmaceutical
  • Shanghai Huilun Pharmaceutical
  • Sichuan Kelun Pharmaceutical
  • Yangtze River Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PDE5 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global PDE5 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.3 PDE5 Inhibitors Market by Type
  6. 1.3.1 Avanafil
  7. 1.3.2 Vardenafil
  8. 1.3.3 Lodenafil
  9. 1.3.4 Mirodenafil
  10. 1.3.5 Tadalafil
  11. 1.3.6 Udenafil
  12. 1.3.7 Sildenafil
  13. 1.3.8 Other
  14. 1.4 Global PDE5 Inhibitors Market Size by Type
  15. 1.4.1 Global PDE5 Inhibitors Market Size Overview by Type (2021-2032)
  16. 1.4.2 Global PDE5 Inhibitors Historic Market Size Review by Type (2021-2026)
  17. 1.4.3 Global PDE5 Inhibitors Forecasted Market Size by Type (2027-2032)
  18. 1.5 Key Regions Market Size by Type
  19. 1.5.1 North America PDE5 Inhibitors Sales Breakdown by Type (2021-2026)
  20. 1.5.2 Europe PDE5 Inhibitors Sales Breakdown by Type (2021-2026)
  21. 1.5.3 Asia-Pacific PDE5 Inhibitors Sales Breakdown by Type (2021-2026)
  22. 1.5.4 South America PDE5 Inhibitors Sales Breakdown by Type (2021-2026)
  23. 1.5.5 Middle East and Africa PDE5 Inhibitors Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 PDE5 Inhibitors Industry Trends
  2. 2.2 PDE5 Inhibitors Industry Drivers
  3. 2.3 PDE5 Inhibitors Industry Opportunities and Challenges
  4. 2.4 PDE5 Inhibitors Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by PDE5 Inhibitors Revenue (2021-2026)
  2. 3.2 Global Top Players by PDE5 Inhibitors Sales (2021-2026)
  3. 3.3 Global Top Players by PDE5 Inhibitors Price (2021-2026)
  4. 3.4 Global PDE5 Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PDE5 Inhibitors Major Company Production Sites & Headquarters
  6. 3.6 Global PDE5 Inhibitors Company, Product Type & Application
  7. 3.7 Global PDE5 Inhibitors Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PDE5 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PDE5 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PDE5 Inhibitors Tier 1, Tier 2, and Tier 3
4 PDE5 Inhibitors Regional Status and Outlook
  1. 4.1 Global PDE5 Inhibitors Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global PDE5 Inhibitors Historic Market Size by Region
  3. 4.2.1 Global PDE5 Inhibitors Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global PDE5 Inhibitors Sales in Value by Region (2021-2026)
  5. 4.2.3 Global PDE5 Inhibitors Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global PDE5 Inhibitors Forecasted Market Size by Region
  7. 4.3.1 Global PDE5 Inhibitors Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global PDE5 Inhibitors Sales in Value by Region (2027-2032)
  9. 4.3.3 Global PDE5 Inhibitors Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 PDE5 Inhibitors by Application
  1. 5.1 PDE5 Inhibitors Market by Application
  2. 5.1.1 Reilly's Phenomena
  3. 5.1.2 Pulmonary Hypertension
  4. 5.1.3 Erectile Dysfunction (ED)
  5. 5.1.4 Other
  6. 5.2 Global PDE5 Inhibitors Market Size by Application
  7. 5.2.1 Global PDE5 Inhibitors Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global PDE5 Inhibitors Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global PDE5 Inhibitors Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America PDE5 Inhibitors Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe PDE5 Inhibitors Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific PDE5 Inhibitors Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America PDE5 Inhibitors Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa PDE5 Inhibitors Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Alkem
  2. 6.1.1 Alkem Company Information
  3. 6.1.2 Alkem Business Overview
  4. 6.1.3 Alkem PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Alkem PDE5 Inhibitors Product Portfolio
  6. 6.1.5 Alkem Recent Developments
  7. 6.2 Amneal Pharmaceuticals
  8. 6.2.1 Amneal Pharmaceuticals Company Information
  9. 6.2.2 Amneal Pharmaceuticals Business Overview
  10. 6.2.3 Amneal Pharmaceuticals PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Amneal Pharmaceuticals PDE5 Inhibitors Product Portfolio
  12. 6.2.5 Amneal Pharmaceuticals Recent Developments
  13. 6.3 Aurobindo Pharma
  14. 6.3.1 Aurobindo Pharma Company Information
  15. 6.3.2 Aurobindo Pharma Business Overview
  16. 6.3.3 Aurobindo Pharma PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Aurobindo Pharma PDE5 Inhibitors Product Portfolio
  18. 6.3.5 Aurobindo Pharma Recent Developments
  19. 6.4 Chartwell
  20. 6.4.1 Chartwell Company Information
  21. 6.4.2 Chartwell Business Overview
  22. 6.4.3 Chartwell PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Chartwell PDE5 Inhibitors Product Portfolio
  24. 6.4.5 Chartwell Recent Developments
  25. 6.5 Cipla
  26. 6.5.1 Cipla Company Information
  27. 6.5.2 Cipla Business Overview
  28. 6.5.3 Cipla PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Cipla PDE5 Inhibitors Product Portfolio
  30. 6.5.5 Cipla Recent Developments
  31. 6.6 Cristália
  32. 6.6.1 Cristália Company Information
  33. 6.6.2 Cristália Business Overview
  34. 6.6.3 Cristália PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Cristália PDE5 Inhibitors Product Portfolio
  36. 6.6.5 Cristália Recent Developments
  37. 6.7 Dong-A Pharmaceutical
  38. 6.7.1 Dong-A Pharmaceutical Company Information
  39. 6.7.2 Dong-A Pharmaceutical Business Overview
  40. 6.7.3 Dong-A Pharmaceutical PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Dong-A Pharmaceutical PDE5 Inhibitors Product Portfolio
  42. 6.7.5 Dong-A Pharmaceutical Recent Developments
  43. 6.8 Dr. Reddy's Laboratories
  44. 6.8.1 Dr. Reddy's Laboratories Company Information
  45. 6.8.2 Dr. Reddy's Laboratories Business Overview
  46. 6.8.3 Dr. Reddy's Laboratories PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Dr. Reddy's Laboratories PDE5 Inhibitors Product Portfolio
  48. 6.8.5 Dr. Reddy's Laboratories Recent Developments
  49. 6.9 Eugia Pharma
  50. 6.9.1 Eugia Pharma Company Information
  51. 6.9.2 Eugia Pharma Business Overview
  52. 6.9.3 Eugia Pharma PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Eugia Pharma PDE5 Inhibitors Product Portfolio
  54. 6.9.5 Eugia Pharma Recent Developments
  55. 6.10 Hetero
  56. 6.10.1 Hetero Company Information
  57. 6.10.2 Hetero Business Overview
  58. 6.10.3 Hetero PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Hetero PDE5 Inhibitors Product Portfolio
  60. 6.10.5 Hetero Recent Developments
  61. 6.11 Lupin
  62. 6.11.1 Lupin Company Information
  63. 6.11.2 Lupin Business Overview
  64. 6.11.3 Lupin PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Lupin PDE5 Inhibitors Product Portfolio
  66. 6.11.5 Lupin Recent Developments
  67. 6.12 Metuchen Pharmaceuticals
  68. 6.12.1 Metuchen Pharmaceuticals Company Information
  69. 6.12.2 Metuchen Pharmaceuticals Business Overview
  70. 6.12.3 Metuchen Pharmaceuticals PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Metuchen Pharmaceuticals PDE5 Inhibitors Product Portfolio
  72. 6.12.5 Metuchen Pharmaceuticals Recent Developments
  73. 6.13 MSN
  74. 6.13.1 MSN Company Information
  75. 6.13.2 MSN Business Overview
  76. 6.13.3 MSN PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 MSN PDE5 Inhibitors Product Portfolio
  78. 6.13.5 MSN Recent Developments
  79. 6.14 SK Chemicals Life Science
  80. 6.14.1 SK Chemicals Life Science Company Information
  81. 6.14.2 SK Chemicals Life Science Business Overview
  82. 6.14.3 SK Chemicals Life Science PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 SK Chemicals Life Science PDE5 Inhibitors Product Portfolio
  84. 6.14.5 SK Chemicals Life Science Recent Developments
  85. 6.15 Sun Pharma
  86. 6.15.1 Sun Pharma Company Information
  87. 6.15.2 Sun Pharma Business Overview
  88. 6.15.3 Sun Pharma PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Sun Pharma PDE5 Inhibitors Product Portfolio
  90. 6.15.5 Sun Pharma Recent Developments
  91. 6.16 Teva
  92. 6.16.1 Teva Company Information
  93. 6.16.2 Teva Business Overview
  94. 6.16.3 Teva PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Teva PDE5 Inhibitors Product Portfolio
  96. 6.16.5 Teva Recent Developments
  97. 6.17 Watson Laboratories
  98. 6.17.1 Watson Laboratories Company Information
  99. 6.17.2 Watson Laboratories Business Overview
  100. 6.17.3 Watson Laboratories PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Watson Laboratories PDE5 Inhibitors Product Portfolio
  102. 6.17.5 Watson Laboratories Recent Developments
  103. 6.18 Zydus
  104. 6.18.1 Zydus Company Information
  105. 6.18.2 Zydus Business Overview
  106. 6.18.3 Zydus PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Zydus PDE5 Inhibitors Product Portfolio
  108. 6.18.5 Zydus Recent Developments
  109. 6.19 Guangzhou Baiyunshan Pharmaceutical
  110. 6.19.1 Guangzhou Baiyunshan Pharmaceutical Company Information
  111. 6.19.2 Guangzhou Baiyunshan Pharmaceutical Business Overview
  112. 6.19.3 Guangzhou Baiyunshan Pharmaceutical PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Guangzhou Baiyunshan Pharmaceutical PDE5 Inhibitors Product Portfolio
  114. 6.19.5 Guangzhou Baiyunshan Pharmaceutical Recent Developments
  115. 6.20 Haisco Pharmaceutical
  116. 6.20.1 Haisco Pharmaceutical Company Information
  117. 6.20.2 Haisco Pharmaceutical Business Overview
  118. 6.20.3 Haisco Pharmaceutical PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Haisco Pharmaceutical PDE5 Inhibitors Product Portfolio
  120. 6.20.5 Haisco Pharmaceutical Recent Developments
  121. 6.21 Pfizer
  122. 6.21.1 Pfizer Company Information
  123. 6.21.2 Pfizer Business Overview
  124. 6.21.3 Pfizer PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Pfizer PDE5 Inhibitors Product Portfolio
  126. 6.21.5 Pfizer Recent Developments
  127. 6.22 Regenex Pharmaceutical
  128. 6.22.1 Regenex Pharmaceutical Company Information
  129. 6.22.2 Regenex Pharmaceutical Business Overview
  130. 6.22.3 Regenex Pharmaceutical PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Regenex Pharmaceutical PDE5 Inhibitors Product Portfolio
  132. 6.22.5 Regenex Pharmaceutical Recent Developments
  133. 6.23 Eli Lilly
  134. 6.23.1 Eli Lilly Company Information
  135. 6.23.2 Eli Lilly Business Overview
  136. 6.23.3 Eli Lilly PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Eli Lilly PDE5 Inhibitors Product Portfolio
  138. 6.23.5 Eli Lilly Recent Developments
  139. 6.24 Qilu Pharmaceutical
  140. 6.24.1 Qilu Pharmaceutical Company Information
  141. 6.24.2 Qilu Pharmaceutical Business Overview
  142. 6.24.3 Qilu Pharmaceutical PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Qilu Pharmaceutical PDE5 Inhibitors Product Portfolio
  144. 6.24.5 Qilu Pharmaceutical Recent Developments
  145. 6.25 Shanghai Huilun Pharmaceutical
  146. 6.25.1 Shanghai Huilun Pharmaceutical Company Information
  147. 6.25.2 Shanghai Huilun Pharmaceutical Business Overview
  148. 6.25.3 Shanghai Huilun Pharmaceutical PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Shanghai Huilun Pharmaceutical PDE5 Inhibitors Product Portfolio
  150. 6.25.5 Shanghai Huilun Pharmaceutical Recent Developments
  151. 6.26 Sichuan Kelun Pharmaceutical
  152. 6.26.1 Sichuan Kelun Pharmaceutical Company Information
  153. 6.26.2 Sichuan Kelun Pharmaceutical Business Overview
  154. 6.26.3 Sichuan Kelun Pharmaceutical PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Sichuan Kelun Pharmaceutical PDE5 Inhibitors Product Portfolio
  156. 6.26.5 Sichuan Kelun Pharmaceutical Recent Developments
  157. 6.27 Yangtze River Pharmaceutical
  158. 6.27.1 Yangtze River Pharmaceutical Company Information
  159. 6.27.2 Yangtze River Pharmaceutical Business Overview
  160. 6.27.3 Yangtze River Pharmaceutical PDE5 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  161. 6.27.4 Yangtze River Pharmaceutical PDE5 Inhibitors Product Portfolio
  162. 6.27.5 Yangtze River Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America PDE5 Inhibitors Sales by Country
  2. 7.1.1 North America PDE5 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America PDE5 Inhibitors Sales by Country (2021-2026)
  4. 7.1.3 North America PDE5 Inhibitors Sales Forecast by Country (2027-2032)
  5. 7.2 North America PDE5 Inhibitors Market Size by Country
  6. 7.2.1 North America PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America PDE5 Inhibitors Market Size by Country (2021-2026)
  8. 7.2.3 North America PDE5 Inhibitors Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe PDE5 Inhibitors Sales by Country
  2. 8.1.1 Europe PDE5 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe PDE5 Inhibitors Sales by Country (2021-2026)
  4. 8.1.3 Europe PDE5 Inhibitors Sales Forecast by Country (2027-2032)
  5. 8.2 Europe PDE5 Inhibitors Market Size by Country
  6. 8.2.1 Europe PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe PDE5 Inhibitors Market Size by Country (2021-2026)
  8. 8.2.3 Europe PDE5 Inhibitors Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific PDE5 Inhibitors Sales by Country
  2. 9.1.1 Asia-Pacific PDE5 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific PDE5 Inhibitors Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific PDE5 Inhibitors Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific PDE5 Inhibitors Market Size by Country
  6. 9.2.1 Asia-Pacific PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific PDE5 Inhibitors Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific PDE5 Inhibitors Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America PDE5 Inhibitors Sales by Country
  2. 10.1.1 South America PDE5 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America PDE5 Inhibitors Sales by Country (2021-2026)
  4. 10.1.3 South America PDE5 Inhibitors Sales Forecast by Country (2027-2032)
  5. 10.2 South America PDE5 Inhibitors Market Size by Country
  6. 10.2.1 South America PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America PDE5 Inhibitors Market Size by Country (2021-2026)
  8. 10.2.3 South America PDE5 Inhibitors Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa PDE5 Inhibitors Sales by Country
  2. 11.1.1 Middle East and Africa PDE5 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa PDE5 Inhibitors Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa PDE5 Inhibitors Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa PDE5 Inhibitors Market Size by Country
  6. 11.2.1 Middle East and Africa PDE5 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa PDE5 Inhibitors Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa PDE5 Inhibitors Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 PDE5 Inhibitors Value Chain Analysis
  2. 12.1.1 PDE5 Inhibitors Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 PDE5 Inhibitors Production Mode & Process
  7. 12.2 PDE5 Inhibitors Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 PDE5 Inhibitors Distributors
  10. 12.2.3 PDE5 Inhibitors Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst